Pembrolizumab + lenvatinib for neuroendocrine tumors

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Apr 2021: Trial registered, NCT04848337
  2. 25 May 2021: Trial started, NCT04848337

The trials

NCT04848337: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

State
Under way
Phase
Phase 2
People
45 taking part
Started
25 May 2021
Primary completion
8 Jan 2025
Arms
Study Treatment Arm
Results
Posted on the registry
  1. 19 Apr 2021: Trial registered
  2. 25 May 2021: Trial started
  3. 12 Feb 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.